Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.

BMC Cancer · 2020 · PMC7014942 · PMID 32046665

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a positive trendP = 0.05actually significant

Only a positive trend was observed between HER2 ECD levels and the presence of visceral disease ( P = 0.05).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.